Exclusion criteria were: the replacement of CNI at any time; acute deterioration

in allograft functions; and serum creatinine level above 3 mg/dL at 12 months. Banff criteria were used for histopathological classification. Progression was defined as delta ci + ct ≥ 2 (difference between 12th month and baseline). Results:  Mean age of patients and donors were 34 ± 11 and 49 ± 10 years. Twelve patients had delayed graft function (DGF). The maintenance regimen consisted of sirolimus (n = 24) and everolimus (n = 11) with mycophenolate mofetil and steroids. Incidence of acute rejection was 25.7%. At baseline, the incidence of nil and mild fibrosis were 80% and 20%, respectively. At 12 months, 17.1% of patients had moderate, 40% had mild and 42.9% had nil fibrosis. Histological progression from baseline to Palbociclib in vitro first year was present in 34% of patients. In multivariate analysis the presence of DGF (P = 0.018) and deceased donor type (P = 0.011) were the most important Kinase Inhibitor Library mw predictors for fibrosis progression. Conclusion:  Progression of graft fibrosis may be seen in one-third of patients under a mTORi-based regimen particularly manifested in deceased donor recipients with subsequent DGF. “
“A clinician may apply the results from randomized controlled trials and population-based cohort studies

to the management of an individual patient to determine whether the patient will achieve more benefit than harm from the intervention. From the data the clinician should determine what are the benefits and harms of the intervention, whether there are any variations in the relative treatment effect, whether the treatment effect varies with different baseline risks of disease in untreated patients, what are the predicted reductions in absolute risk of disease for individuals and whether the benefits outweigh the risks for their patient. If the patient is at a low risk of the outcome, the harms

of therapy may not justify its use to prevent or treat the disease. However, if the patient is at a high risk of developing the outcome, he or she is likely to gain more benefit than harm from the therapy. “
“Aim:  Both vascular calcification and atherosclerosis are highly prevalent in patients with end-stage renal disease (ESRD) and have been associated with increased cardiovascular Sodium butyrate morbidity. Because those two phenomena might be only coincidentally related in chronic haemodialysis (HD) patients, in this study, coronary artery calcification (CAC), common carotid artery intima media thickness (CCA-IMT) and thickness of atherosclerotic plaques in the carotid artery were simultaneously measured. Methods:  In a cross-sectional study of 47 HD patients (31 male, mean age 56.8 ± 11.4 years, and 16 female, mean age 56.0 ± 7.5 years) without history of major cardiovascular complications. CCA-IMT and presence and thickness of atherosclerotic plaques were measured with ultrasound and CAC with multidetector computed tomography. Results:  The CAC were present in 70.2% of patients.